PD-1 immunotherapy serves to increase the antitumor activity of T cells in the body by relieving the suppression of immune function, which is mediated as a result of the combination of PD-1 and PDL-1, thus providing a killing and suppressing impact on cancer cells [36]. This evidence concerns the gene PDCD1 and cancer.